Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients

Marianna Pelloni, Giulia Coltrinari, Donatella Paoli, Francesco Pallotti, Francesco Lombardo, Andrea Lenzi, Loredana Gandini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Various microRNAs from the miR-371-3 and miR-302a–d clusters have recently been proposed as markers for testicular germ cell tumours. Upregulation of these miRNAs has been found in both the tissue and serum of testicular cancer patients, but they have never been studied in human seminal plasma. The aim of this study was, therefore, to assess the differences in the expression of miR-371-3 and miR-302a–d between the seminal plasma and serum of testicular cancer patients, and to identify new potential testicular cancer markers in seminal plasma. We investigated the serum and seminal plasma of 28 pre-orchiectomy patients subsequently diagnosed with testicular cancer, the seminal plasma of another 20 patients 30 days post-orchiectomy and a control group consisting of 28 cancer-free subjects attending our centre for an andrological check-up. Serum microRNA expression was analysed using RT-qPCR. TaqMan Array Card 3.0 platform was used for microRNA profiling in the seminal plasma of cancer patients. Results for both miR-371-3 and the miR-302 cluster in the serum of testicular cancer patients were in line with literature reports, while miR-371and miR-372 expression in seminal plasma showed the opposite trend to serum. On array analysis, 37 miRNAs were differentially expressed in the seminal plasma of cancer patients, and the upregulated miR-142 and the downregulated miR-34b were validated using RT-qPCR. Our study investigated the expression of miRNAs in the seminal plasma of patients with testicular cancer for the first time. Unlike in serum, miR-371-3 cannot be considered as markers in seminal plasma, whereas miR-142 levels in seminal plasma may be a potential marker for testicular cancer.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalEndocrine
DOIs
Publication statusAccepted/In press - Oct 28 2016

Fingerprint

Testicular Neoplasms
Semen
MicroRNAs
Serum
Orchiectomy
Neoplasms
Up-Regulation
Down-Regulation
Control Groups

Keywords

  • miR-142
  • miR-371-3
  • Seminal plasma
  • Testicular cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Pelloni, M., Coltrinari, G., Paoli, D., Pallotti, F., Lombardo, F., Lenzi, A., & Gandini, L. (Accepted/In press). Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. Endocrine, 1-10. https://doi.org/10.1007/s12020-016-1150-z

Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. / Pelloni, Marianna; Coltrinari, Giulia; Paoli, Donatella; Pallotti, Francesco; Lombardo, Francesco; Lenzi, Andrea; Gandini, Loredana.

In: Endocrine, 28.10.2016, p. 1-10.

Research output: Contribution to journalArticle

Pelloni, Marianna ; Coltrinari, Giulia ; Paoli, Donatella ; Pallotti, Francesco ; Lombardo, Francesco ; Lenzi, Andrea ; Gandini, Loredana. / Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. In: Endocrine. 2016 ; pp. 1-10.
@article{9d9e8f67e4984844923284f9c0f848ed,
title = "Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients",
abstract = "Various microRNAs from the miR-371-3 and miR-302a–d clusters have recently been proposed as markers for testicular germ cell tumours. Upregulation of these miRNAs has been found in both the tissue and serum of testicular cancer patients, but they have never been studied in human seminal plasma. The aim of this study was, therefore, to assess the differences in the expression of miR-371-3 and miR-302a–d between the seminal plasma and serum of testicular cancer patients, and to identify new potential testicular cancer markers in seminal plasma. We investigated the serum and seminal plasma of 28 pre-orchiectomy patients subsequently diagnosed with testicular cancer, the seminal plasma of another 20 patients 30 days post-orchiectomy and a control group consisting of 28 cancer-free subjects attending our centre for an andrological check-up. Serum microRNA expression was analysed using RT-qPCR. TaqMan Array Card 3.0 platform was used for microRNA profiling in the seminal plasma of cancer patients. Results for both miR-371-3 and the miR-302 cluster in the serum of testicular cancer patients were in line with literature reports, while miR-371and miR-372 expression in seminal plasma showed the opposite trend to serum. On array analysis, 37 miRNAs were differentially expressed in the seminal plasma of cancer patients, and the upregulated miR-142 and the downregulated miR-34b were validated using RT-qPCR. Our study investigated the expression of miRNAs in the seminal plasma of patients with testicular cancer for the first time. Unlike in serum, miR-371-3 cannot be considered as markers in seminal plasma, whereas miR-142 levels in seminal plasma may be a potential marker for testicular cancer.",
keywords = "miR-142, miR-371-3, Seminal plasma, Testicular cancer",
author = "Marianna Pelloni and Giulia Coltrinari and Donatella Paoli and Francesco Pallotti and Francesco Lombardo and Andrea Lenzi and Loredana Gandini",
year = "2016",
month = "10",
day = "28",
doi = "10.1007/s12020-016-1150-z",
language = "English",
pages = "1--10",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients

AU - Pelloni, Marianna

AU - Coltrinari, Giulia

AU - Paoli, Donatella

AU - Pallotti, Francesco

AU - Lombardo, Francesco

AU - Lenzi, Andrea

AU - Gandini, Loredana

PY - 2016/10/28

Y1 - 2016/10/28

N2 - Various microRNAs from the miR-371-3 and miR-302a–d clusters have recently been proposed as markers for testicular germ cell tumours. Upregulation of these miRNAs has been found in both the tissue and serum of testicular cancer patients, but they have never been studied in human seminal plasma. The aim of this study was, therefore, to assess the differences in the expression of miR-371-3 and miR-302a–d between the seminal plasma and serum of testicular cancer patients, and to identify new potential testicular cancer markers in seminal plasma. We investigated the serum and seminal plasma of 28 pre-orchiectomy patients subsequently diagnosed with testicular cancer, the seminal plasma of another 20 patients 30 days post-orchiectomy and a control group consisting of 28 cancer-free subjects attending our centre for an andrological check-up. Serum microRNA expression was analysed using RT-qPCR. TaqMan Array Card 3.0 platform was used for microRNA profiling in the seminal plasma of cancer patients. Results for both miR-371-3 and the miR-302 cluster in the serum of testicular cancer patients were in line with literature reports, while miR-371and miR-372 expression in seminal plasma showed the opposite trend to serum. On array analysis, 37 miRNAs were differentially expressed in the seminal plasma of cancer patients, and the upregulated miR-142 and the downregulated miR-34b were validated using RT-qPCR. Our study investigated the expression of miRNAs in the seminal plasma of patients with testicular cancer for the first time. Unlike in serum, miR-371-3 cannot be considered as markers in seminal plasma, whereas miR-142 levels in seminal plasma may be a potential marker for testicular cancer.

AB - Various microRNAs from the miR-371-3 and miR-302a–d clusters have recently been proposed as markers for testicular germ cell tumours. Upregulation of these miRNAs has been found in both the tissue and serum of testicular cancer patients, but they have never been studied in human seminal plasma. The aim of this study was, therefore, to assess the differences in the expression of miR-371-3 and miR-302a–d between the seminal plasma and serum of testicular cancer patients, and to identify new potential testicular cancer markers in seminal plasma. We investigated the serum and seminal plasma of 28 pre-orchiectomy patients subsequently diagnosed with testicular cancer, the seminal plasma of another 20 patients 30 days post-orchiectomy and a control group consisting of 28 cancer-free subjects attending our centre for an andrological check-up. Serum microRNA expression was analysed using RT-qPCR. TaqMan Array Card 3.0 platform was used for microRNA profiling in the seminal plasma of cancer patients. Results for both miR-371-3 and the miR-302 cluster in the serum of testicular cancer patients were in line with literature reports, while miR-371and miR-372 expression in seminal plasma showed the opposite trend to serum. On array analysis, 37 miRNAs were differentially expressed in the seminal plasma of cancer patients, and the upregulated miR-142 and the downregulated miR-34b were validated using RT-qPCR. Our study investigated the expression of miRNAs in the seminal plasma of patients with testicular cancer for the first time. Unlike in serum, miR-371-3 cannot be considered as markers in seminal plasma, whereas miR-142 levels in seminal plasma may be a potential marker for testicular cancer.

KW - miR-142

KW - miR-371-3

KW - Seminal plasma

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84992740342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992740342&partnerID=8YFLogxK

U2 - 10.1007/s12020-016-1150-z

DO - 10.1007/s12020-016-1150-z

M3 - Article

AN - SCOPUS:84992740342

SP - 1

EP - 10

JO - Endocrine

JF - Endocrine

SN - 1355-008X

ER -